drugset / Trial / NCT01874314
Effects of SQ109 on QTc Interval in Healthy Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
This will be a single center, open label, crossover study to evaluate the safety and tolerability of multiple dose levels of SQ109.
Timeline
- Start
- —
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Moxifloxacin | Small molecule | 400 mg | Oral |
| Subject | SQ109 | Small molecule | 300 mg | Oral |
| Subject | SQ109 | Small molecule | 450 mg | Oral |